Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Drug Metabolism and Bioanalysis Letters
  4. Volume 17, Issue 2
  5. Article
Volume 17, Issue 2
  • ISSN: 2949-6810
  • E-ISSN: 2949-6829

Abstract

Background

Efinaconazole is a topical antifungal medication that is effective against fungal infections of the toenails. In addition, due to its application on the skin, minimal systemic absorption takes place on the epidermic layer, which leads to the availability of lower-level concentration in the bloodstream. Although several reported methods in the literature describe the quantification of Efinaconazole using conventional techniques like HPTLC and HPLC, these methods lack the necessary sensitivity and selectivity to be directly applied for quantification in biological samples.

Objective

Current research work aimed to develop a rapid, specific, selective, and sensitive method using plasma as one of the biological samples for quantification of Efinaconazole (EZ) in the presence of Fluconazole (FZ) as an internal standard by tandem mass spectrometry (LC-MS/MS).

Methods

Chromatographic separation was achieved with a Thermo Hypersil Gold (100 mm x 2.1 mm, 1.9 µm) UPLC column using a mobile phase composed of 20% formic acid-water (0.1%) and 80% methanol. Liquid-liquid extraction (LLE) was employed for sample preparation. Efinaconazole and the internal standard were detected using the heated electrospray ionization (HESI) technique in parallel reaction monitoring (PRM) mode.

Results

The developed method displayed a linearity range of 1 to 2000 pg/mL (0.001-2 ng/mL). Precision and accuracy for the lower limit of quantitation, low, mid, and high-quality control (QC) levels demonstrated a variance of less than 5% and an accuracy of 99 to 103%. Long-term stability was confirmed under various conditions, including storage in an auto-sampler, at room temperature, in a deep freezer, and after freeze-thaw cycles.

Conclusion

The validated LC-MS/MS method has exceptional sensitivity, specificity, selectivity, rapid analysis, minimal requirement of sample quantity, wide dynamic range of concentration, robustness, and reproducibility, making it an indispensable tool, especially in fields of Permeation Testing (IVPT), Release Testing (IVRT), Pharmacokinetic, Toxicology, Clinical studies, and in drug development program for the quantification of Efinaconazole.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/dmbl/10.2174/0118723128348675241129100845
2024-12-13
2025-04-07

  • From This Site

    /content/journals/dmbl/10.2174/0118723128348675241129100845
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ScherR.K. CoppaL.M. Advances in the diagnosis and treatment of onychomycosis.Hosp. Med.1998341120
     [Google Scholar]
  2. GuptaA.K. GuptaA. Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: A multicenter Canadian survey of 35,000 patients.J. Am. Acad. Dermatol.200450310110.1016/j.jaad.2003.10.329
     [Google Scholar]
  3. GhannoumM.A. HajjehR.A. ScherR. KonnikovN. GuptaA.K. SummerbellR. SullivanS. DanielR. KrusinskiP. FleckmanP. RichP. OdomR. AlyR. PariserD. ZaiacM. RebellG. LesherJ. GerlachB. Ponce-de-Leon b, G.F.; Ghannoum a, A.; Warner, J.; Isham, N.; Elewski, B. A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns.J. Am. Acad. Dermatol.200043464164810.1067/mjd.2000.107754 11004620
     [Google Scholar]
  4. IorizzoM. PiracciniB.M. TostiA. Today’s treatments options for onychomycosis.J. Dtsch. Dermatol. Ges.201081187587910.1111/j.1610‑0387.2010.07499.x 20738460
     [Google Scholar]
  5. DiCenzoR. FrerichsV. LarppanichpoonpholP. PredkoL. ChenA. ReichmanR. MorrisM. Effect of quercetin on the plasma and intracellular concentrations of saquinavir in healthy adults.Pharmacotherapy20062691255126110.1592/phco.26.9.1255 16945047
     [Google Scholar]
  6. GuptaA.K. JosephW.S. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States.J. Am. Podiatr. Med. Assoc.2000901049550110.7547/87507315‑90‑10‑495 11107710
     [Google Scholar]
  7. YangD. MichelL. ChaumontJ.P. Millet-ClercJ. Use of caryophyllene oxide as an antifungal agent in an in vitro experimental model of onychomycosis.Mycopathologia19991482798210.1023/A:1007178924408 11189747
     [Google Scholar]
  8. GlynnM. JoW. MinowaK. SanadaH. NejishimaH. MatsuuchiH. OkamuraH. PillaiR. MutterL. Efinaconazole: Developmental and reproductive toxicity potential of a novel antifungal azole.Reprod. Toxicol.201552182510.1016/j.reprotox.2014.12.007 25527861
     [Google Scholar]
  9. TatsumiY. NagashimaM. ShibanushiT. IwataA. KangawaY. InuiF. SiuW.J.J. PillaiR. NishiyamaY. Mechanism of action of efinaconazole, a novel triazole antifungal agent.Antimicrob. Agents Chemother.20135752405240910.1128/AAC.02063‑12 23459486
     [Google Scholar]
  10. LipnerS. ScherR. Efinaconazole in the treatment of onychomycosis.Infect. Drug Resist.2015816317210.2147/IDR.S69596 26082652
     [Google Scholar]
  11. Jo SiuW.J. TatsumiY. SendaH. PillaiR. NakamuraT. SoneD. FothergillA. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.Antimicrob. Agents Chemother.20135741610161610.1128/AAC.02056‑12 23318803
     [Google Scholar]
  12. Tupaki-SreepurnaA. JishnuB. ThanneruV. SharmaS. GopiA. SundaramM. Jyoti KindoA. An assessment of in vitro antifungal activities of efinaconazole and itraconazole against common non-dermatophyte fungi causing onychomycosis.J. Fungi2017322010.3390/jof3020020 29371538
     [Google Scholar]
  13. BhattV. PillaiR. Efinaconazole topical solution, 10%: Formulation development program of a new topical treatment of toenail onychomycosis.J. Pharm. Sci.201510472177218210.1002/jps.24459 25940933
     [Google Scholar]
  14. JarrattM. SiuW.J. YamakawaE. KoderaN. PillaiR. SmithK. Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis.J. Drugs Dermatol.201312910101016 24002148
     [Google Scholar]
  15. LiP.J. PengQ.D. HuG. GengJ. Determination of four enantiomers in Efinaconazole by HPLC.Chin. J. Pharm.20164714421444
     [Google Scholar]
  16. PatelR.B. PatelM.R. PatniN.R. AgrawalV. Efinaconazole: DoE-supported development and validation of a quantitative HPTLC method and its application for the assay of drugs in solution and microemulsion-based formulations.Anal. Methods202012101380138810.1039/C9AY02599E
     [Google Scholar]
  17. VikasA. RashminP. MrunaliP. SandipM. KaushikT. RP-HPLC method for quantitative estimation of Efinaconazole in topical microemulsion and microemulsion-based-gel formulations and in presence of its degradation products.Microchem. J.202015510475310.1016/j.microc.2020.104753
     [Google Scholar]
  18. KolimiP. ShankarV.K. ShettarA. RangappaS. RepkaM.A. MurthyS.N. Development and validation of HPLC method for efinaconazole: Application to human nail permeation studies.AAPS PharmSciTech20222316310.1208/s12249‑021‑02196‑3 35091878
     [Google Scholar]
  19. UppalaR. MaruthapillaiA. Quantification of potential genotoxic impurity IMP-A and IMP-B in efinaconazole drug material by LC-MS/MS.Mater. Today Proc.202140S198S20510.1016/j.matpr.2020.08.810
     [Google Scholar]
  20. GovindarajanS. AsharaniI.V. Development and validation of a LC–MS/MS method for the profiling of impurities formed during stress study of antifungal agent—Efinaconazole.J. Chromatogr. Sci.202260432433510.1093/chromsci/bmab079 34160008
     [Google Scholar]
  21. FDA Home page. Guidance for Industry: Bioanalytical Method Validation.2018 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance
  22. JadavT. RajputN. SahuA.K. SenguptaP. LC-QQQ-MS based intracellular quantification of bictegravir in peripheral blood mononuclear cells and plasma.Anal. Biochem.202366711508410.1016/j.ab.2023.115084 36806669
     [Google Scholar]
  23. JogpetheA. JadavT. RajputN. Kumar SahuA. DasR. GuptaA. ShardA. SenguptaP. LC/Q-TOF MS and LC/QQQ MS based bioanalysis of a new ferrocene derivative as a potential anticancer lead with promising drug-like characteristics.J. Chromatogr. B.2022121012346910.1016/j.jchromb.2022.123469 36137491
     [Google Scholar]
  24. Van EeckhautA. LanckmansK. SarreS. SmoldersI. MichotteY. Validation of bioanalytical LC–MS/MS assays: Evaluation of matrix effects.J. Chromatogr. B.2009877232198220710.1016/j.jchromb.2009.01.003 19179125
     [Google Scholar]
  25. DhakneP. SahuA.K. SharmaM.K. SenguptaP. Simultaneous quantification of abemaciclib and letrozole in rat plasma: Method development, validation and pharmacokinetic application.Biomed. Chromatogr.2020346e482510.1002/bmc.4825 32166756
     [Google Scholar]
  26. NemaniK.S. ShardA. SenguptaP. Establishment of a quantitative bioanalytical method for an acetylcholinesterase inhibitor Ethyl 3-(2-(4-fluorophenyl) amino)-4-phenylthiazol-5-yl)-3-oxopropanoate including its physicochemical characterization and in vitro metabolite profiling using liquid chromatography-mass spectrometry.J. Chromatogr. B.2018109621422210.1016/j.jchromb.2018.08.019 30179754
     [Google Scholar]
  27. SantosS.R.C.J. CamposE.V. SanchesC. GomezD.S. FerreiraM.C. Fluconazole plasma concentration measurement by liquid chromatography for drug monitoring of burn patients.Clinics201065223724310.1590/S1807‑59322010000200017 20186309
     [Google Scholar]
  28. WallaceJ.E. HarrisS.C. GallegosJ. FouldsG. ChenT.J. RinaldiM.G. Assay of fluconazole by high-performance liquid chromatography with a mixed-phase column.Antimicrob. Agents Chemother.199236360360610.1128/AAC.36.3.603 1622169
     [Google Scholar]
  29. Flores-MurrietaF.J. Granados-SotoV. HongE. A simple and rapid method for determination of fluconazole in human plasma samples by high-performance liquid chromatography.J. Liq. Chromatogr.199417173803381110.1080/10826079408013995
     [Google Scholar]
/content/journals/dmbl/10.2174/0118723128348675241129100845
Loading
Determination of Efinaconazole in Plasma using Validated LC-MS/MS Technique
Drug Metab. Bioanal. Lett. 17, 76 (2024); https://doi.org/10.2174/0118723128348675241129100845
/content/journals/dmbl/10.2174/0118723128348675241129100845
/content/journals/dmbl/10.2174/0118723128348675241129100845
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): efinaconazole; fluconazole; human plasma; LC-MS/MS; US-FDA; validation

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test